29 March 2016 in Surgical Infections
Background: Fournier gangrene (FG) is a fulminant necrotizing infection of the perineal, perianal, and periurethral tissues. The Laboratory Risk Indicator for Necrotizing Fasciitis (LRINEC) scale is used for diagnosis of necrotizing fasciitis. However, data on its relevance and usefulness in FG are lacking. The aim of this study was to evaluate the utility of the LRINEC scale in predicting the outcome of FG. Methods: This retrospective case study included 41 patents with FG treated at our institution from 2000 to 2013. The patients were divided into survivors and non-survivors. Results: The mortality rate was 22%. The median age (75 vs. 62.5 y; p = 0.013), rate of co-existing diabetes mellitus (66.7% vs. 3.1%; p < 0.001), and median affected skin surface (4% vs. 1%; p < 0.001) were greater in the non-survivors. Seven of nine patients (77.8%) who did not survive (compared with 37.5% who survived) had a polymicrobial infection (p = 0.032). Of all the causative pathogens isolated, Proteus mirabilis was more common in non-survivors (55.6% vs. 6.3%; p = 0.001). The median calculated LRINEC score for survivors was 5 compared with 10 for the non-survivors (p < 0.001). Regression analysis showed that all the aforementioned variables, except for polymicrobial culture, were significant risk factors for predicting death. The area under the receiver operating characteristic curve for the LRINEC score was the highest, 0.976 (95% confidence interval 0.872–0.999; p < 0.0001), and the cut-off value was ≥9 with 93.7% specificity and 100% susceptibility for the prediction of a lethal outcome. Conclusions: The LRINEC score could be used for prediction of disease severity and outcomes. A threshold of 9 could be a high-value predictor of death during the initial evaluation of patients with FG.
1 January 2011 in Central European Journal of Urology
AMAivaras Jonas Matjošaitis
Aivaras Jonas Matjošaitis
The aim of study was to establish pretreatment and postoperative factors which could predict the early biochemical recurrence after radical prostatectomy. 754 patients had undergone radical prostatectomy since January 2002 to December 2008 in our department and were included in this prospective study. Exclusion criteria were: neoadjuvant or adjuvant treatment (radiation or hormonal treatment) and N+. Following parameters were evaluated: age, PSA at time of biopsy, time period from biopsy to operation, biopsy and postoperative Gleason score, stage, high grade intraepithelial neoplasias, perineural invasion. Biochemical recurrence was detected if PSA value after radical prostatectomy was ≥0.2 ng/ml. All factors likely to be predictive were evaluated by univariate analysis (Log-rank test). Multivariate analysis using Cox model was completed for all factors with p value 10 ng/ml (HR 2.45, p = 0.008), pathological stage ≥pT3 (HR 2.371, p = 0.02), postoperative Gleason score ≥7 (HR 2.149, p = 0.049), positive surgical margins (HR 2.482, p = 0.014) and absence of high grade intraepithelial neoplasia in removed prostate (HR 0.358, p = 0.006) are independent factors influencing biochemical recurrence after radical prostatectomy. Patients with higher PSA, locally advanced disease, positive surgical margins, and Gleason score ≥7 are at the highest risk for biochemical recurrence.
1 January 2026 in Open Medicine
Objectives: To compare the QoL of patients diagnosed with low- or favorable-intermediate-risk PCa after focal HDR brachytherapy and active surveillance. Our secondary objectives were to compare progression-free survival (PFS) between patients who underwent focal treatment and those who were actively surveilled and to assess early and late GU and GI adverse effects after the focal HDR brachytherapy. Methods: This prospective randomized controlled trial was conducted at the National Cancer Center located in Vilnius, Lithuania. The study was initiated after approval from the Vilnius Regional Biomedical Research Ethics Committee was obtained (Approval ID 2022/6-1438-911). Twenty-seven patients were assigned to the AS group and 28 to the focal HDR group. Results: During the median follow-up time of 14 and 17 months for AS and HDR groups, respectively, the QoL, evaluated by the EORTC QLQ-30 and PR25 instruments, showed no statistically significant differences in functional scores between the groups after baseline adjustment. Additionally, patients in the HDR group reported better urinary outcomes as measured by EORTC PR25 and IPSS scores at 6, 12, and 18 months. There were no statistically significant differences in erectile function between the groups as measured by the IIEF. Early toxicity was low (no Grade ≥3 events), and only two cases (7.1 %) of Grade 2 GU toxicity were reported in the HDR group within the first 3 months, with one case persisting for 6 months. Late toxicity was not assessed during this interim follow-up. The HDR group demonstrated a non-significant trend toward better oncological outcomes, with fewer PSA-based recurrences and a higher mean PFS than the AS. At the time of last follow-up, 49/55 (89 %) patients were censored (22/27 in the AS and 27/28 in the HDR group). Conclusions: A current study shows comparable QoL and early toxicity results between AS and HDR groups. Any domain-level signals were below MCID and did not persist after baseline adjustment. Results of PFS are underpowered at this interim analysis due to short follow-up and high censoring, and should be considered hypothesis-generating only. However, as current results are only exploratory and insufficient to assess durable disease control or late toxicity, a longer follow-up, larger cohorts, and a multicenter approach are needed to provide definitive outcomes to demonstrate the benefit of focal brachytherapy.
7 November 2019 in Research Square
LDLinkeviciute-Ulinskiene Donata
Linkeviciute-Ulinskiene Donata
Background: The aim of this study was to determine whether type 2 diabetes mellitus and treatment with metformin is associated with prostate cancer risk. Methods: Male patients with diagnosis of type 2 diabetes during the period of 2000 – 2016 were identified in the National Health Insurance Fund database. The prostate cancer cases were identified by pooling these records from the national Cancer Registry. The calculation of prostate cancer stardardized incidence ratios (SIRs) was composed as a ratio of observed number of cancer case in people with diagnosis of diabetes to the expected number of cancer cases in the underlying general population. Results: Overall, 64,000 males diagnosed with diabetes in Lithuania between 2000 and 2016 were included in the final cohort. 2,754 prostate cancers were observed versus 3,111.26 expected within the period of observation entailing an SIR of 0.89 (95% CI: 0.85–0.92). Significantly lower risk of prostate cancer was found in diabetes patients in all age groups, there were no differences in prostate cancer risk by time since diagnosis of diabetes. Significantly lower risk of prostate cancer also was found in both metformin users and never-users’ groups, with higher risk reduction in metformin users (SIR 0.71, 95% CI: 0.68–0.75) than in diabetes patients never-users (SIR 0.88, 95% CI: 0.80–0.96). Conclusions: In this large population-based study we found a significantly decreased risk of prostate cancer among men with diabetes and metformin users. However, the risk of prostate cancer showed no clear trend with diabetes duration and cumulative metformin dose.